Evaluation of novel treatments in biochemically recurrent prostate

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

We have completed 2 trials of antigen directed immunotherapy in prostate cancer. We were able to show for the first time that such therapies can be associated with PSA declines (perhaps delayed) and decreased tumor volume on PSMA imaging. We have completed a study of short course enzalutamide that demonstrated for the first time the potential efficacy of intermittent enzalutamide in biochemically recurrent prostate cancer. This benefit was later confirmed in a phase 3 trial. We have completed a study of short course enzalutamide that demonstrated for the first time that enzalutamide treatment was associated with decreased myeloid suppressor cells and increases in natural killer cells. This formed to basis of future clinical trials. We presented data this year that demonstrated for the first time the clinical impact on PSA and PSMA imaging of Radium 223 in biochemically recurrent prostate cancer. We have initiated the first combination study of an androgen receptor pathway inhibitor (enzalutamide) and an immunocytokine in biochemically recurrent prostate cancer. Preliminary data will be presented in early 2026.